SPLASH BEverage GROUP Enters Collaboration to Develop Veterinary Drug

What Happened

• SPLASH BEVERAGE GROUP, INC. (filed 8‑K Aug 4, 2026) entered a Development and Collaboration Agreement dated July 31, 2026 with Lupvindol Biosciences Ltd. to lead development and FDA regulatory work for a new animal drug derived from the company’s CannEpil® product (licensed from Argent Biopharma).
• Lupvindol will pursue an Investigational New Animal Drug (INAD) with the FDA Center for Veterinary Medicine and seek Conditional Approval under Section 571 of the Federal Food, Drug, and Cosmetic Act, handling preclinical/clinical studies, the Product Development Plan, filing for approval, and supporting commercialization and licensing.

Key Details

• Milestone payments total up to $1,110,000 in cash: $95,000 at signing; $75,000 at INAD opening; $65,000 at Product Development Plan completion; $125,000 at program submission inflection point; $250,000 at filing for Conditional Approval; $500,000 upon Conditional Approval or earlier license.
• Upon Conditional Approval (or earlier licensing), Lupvindol also receives an ongoing royalty of 4% of net sales (terminating 10 years after first commercial sale), or Lupvindol may elect to receive common stock instead (valued by greater of 5‑day VWAP or NYSE American minimum issuance price).
• Agreement term: initial 5 years (automatic one‑year renewals unless 90 days’ notice). Splash can terminate for convenience with 90 days’ notice but must pay accrued milestones and a wind‑down fee equal to 100% of the next unearned milestone. Other termination rights exist for missed milestones, material FDA communications, insolvency, or failure to cure material defaults.

Why It Matters

• This deal advances Splash’s strategy to commercialize a pharmaceuticals-derived product into the veterinary market without Lupvindol taking equity; Lupvindol carries regulatory and development lead responsibilities.
• Financial impact for investors: Splash commits up to ~$1.11M of milestone funding and may face future royalty payments of 4% of net sales or potential share issuance (dilution) instead of royalties if Lupvindol elects stock. Material upside for Splash depends on successful FDA Conditional Approval or a licensing transaction.
• Risks are development and regulatory uncertainty (FDA approval is not guaranteed) and conditional cash or equity obligations tied to progress and approval milestones.